[DATE]

[DR. NAME]

[PRACTICE/FACILITY NAME]

[STREET]

[CITY, STATE] [ZIP CODE]

Dear Dr. [LAST NAME]:

We are pleased to announce that patients with suspected CAD can now be referred to [PRACTICE/FACILITY NAME] to receive a non-invasive CCTA ± HeartFlow FFRCT Analysis. This is the first technology that uses standard coronary CTA scans to provide insights into anatomy and physiology in the diagnosis of CAD.

The CCTA ± HeartFlow FFRCT process:

1. If a patient has suspected coronary artery disease, a clinician may order a standard CCTA scan to look at the anatomy for blockages.

2. If additional information is needed, a HeartFlow FFRCT Analysis may be ordered to better understand the functional impact of the blockage (physiology/blood flow).

3. Leveraging advanced algorithms incorporating AI and computational fluid dynamics, the HeartFlow FFRCT Analysis digital 3D model is built, showing how each blockage limits blood flow.

4. Within hours, the clinician receives the HeartFlow FFRCT Analysis via a secure web interface and can assess, vessel by vessel, if sufficient blood flow is reaching the heart to better determine the best treatment path.

A CCTA ± FFRCT first pathway has been supported by the ACC/AHA Chest Pain Guidelines and is already adopted by more than 725 hospitals worldwide, including 80% of the Top 50 Heart Hospitals in the US. New level 1 clinical evidence from the PRECISE trial, just presented as part of the Late-Breaking Clinical Sessions at AHA 2022, now shows that the CCTA ±FFRCT-centered strategy is a frontline diagnostic pathway for patients with suspected CAD.

Please feel free to contact me at [PHONE NUMBER] or [EMAIL] for further information on the HeartFlow Analysis. I look forward to working together to improve the cardiovascular care for our patients.

Sincerely,

[NAME, TITLE]